Definium Therapeutics shares rise after positive DT120 anxiety study
Definium Therapeutics reported positive topline results from its Phase 3 study of DT120, an orally disintegrating tablet for adults with generalized anxiety disorder.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.